Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612000294853
Ethics application status
Approved
Date submitted
23/02/2012
Date registered
14/03/2012
Date last updated
14/03/2012
Type of registration
Retrospectively registered
Titles & IDs
Public title
A trial to compare highly purified human menopausal gonadotropins (hMG) and recombinant follicular stimulating hormone (rFSH) to improve pregnancy rates in infertile women
Query!
Scientific title
A randomised open-label trial comparing highly purified human menopausal gonadotropins (hMG) and recombinant follicular stimulating hormone (rFSH) in a gonadotrophin releasing hormone (GnRH) agonist cycle for infertile women to improve pregnancy rates
Query!
Secondary ID [1]
280025
0
'Nil'
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
infertility
285937
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
286126
286126
0
0
Query!
Fertility including in vitro fertilisation
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
120 infertility patients randomly divided in two groups. Highly purified human menopausal gonadotrophine(menopur) 150IU once a day was given to first group, recombinant FSH(Gonal F)150IU once a day was given to second group for IVF/ICSI cycles.These drugs were given every day subcutaneously, beginning from third day of menstrual cycle up to the day that two or more follicles greater than 17mm in diameter were seen by ultrasonography
Query!
Intervention code [1]
284345
0
Treatment: Drugs
Query!
Comparator / control treatment
rFSH treatment of 60 infertile women
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
286602
0
clinical pregnancy rate which will be confirmed by getational sac seen by ultrasonography
Query!
Assessment method [1]
286602
0
Query!
Timepoint [1]
286602
0
three months
Query!
Secondary outcome [1]
296246
0
rate of hyperstimulation which will be determined by enlarged diameter of ovaries with multiple cysts(>7cm), hemoconcentration findings in blood count, hypoproteinemia and free fluid collection in pouch of Douglas.
Query!
Assessment method [1]
296246
0
Query!
Timepoint [1]
296246
0
three months
Query!
Eligibility
Key inclusion criteria
normal uterine anatomy having tubal factor and/or male factor or unexplained infertility Inclusion criterias, infertility duration were more than two years, whose basal FSH were between 2-12 IU/L and whose body mass indexes less than 35kg/m2 were included
Query!
Minimum age
23
Years
Query!
Query!
Maximum age
36
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Women with previous faiure of IVF cycles, women with systemic and/or endocrine diseases, women with recurrent early pregnancy losses were excluded.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
23/05/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
120
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
4171
0
Turkey
Query!
State/province [1]
4171
0
Query!
Funding & Sponsors
Funding source category [1]
284781
0
University
Query!
Name [1]
284781
0
ISTANBUL UNIVERSITY
Query!
Address [1]
284781
0
Istanbul Universitesi Arastirma Fonu, Beyazit/Fatih 34760 Istanbul
Query!
Country [1]
284781
0
Turkey
Query!
Primary sponsor type
University
Query!
Name
ISTANBUL UNIVERSITY
Query!
Address
Istanbul Universitesi Arastirma Fonu, Beyazit/Fatih 34760 Istanbul
Query!
Country
Turkey
Query!
Secondary sponsor category [1]
283668
0
None
Query!
Name [1]
283668
0
none
Query!
Address [1]
283668
0
none
Query!
Country [1]
283668
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Summary
Brief summary
Objective: Our aims were to compare hpHMG and rFSH for the duration of treatment, doses of the drugs used , the number of oocytes retrieved, the number of embryos obtained and hormonal status of the patients during ovarian stimulation. Material & methods: 120 infertility patients were recruited and randomly divided into two groups.First group used hpHMG , other group used rFSH for ovulation induction before IVF. Long protocol GnRH agonist was started at 21st day of stimulation.Transvaginal ultrasonography was performed at third and eighth day of the cycle, if ovarian cyst > 20 mm was not exist, stimulation was started. Blood samples were taken at third and eighth day of the cycle , for serum levels of estradiol (E2), progesterone (P), androstenedione (A), free testosterone (fT) and dehydroepiandrosterone sulfate (DHEA-S).When two or more follicles greater than 17 mm were observed, 10.000 IU HCG was applied inramuscularly. Follicles were collected after 36 hours from the HCG injection by transvaginal USG, using 17 gauge needles.Endometrial thickness was recorded. Aspiration of each follicle 10 millimeters and above was made. Blood samples were taken again at the day of follicle aspiration day for hormonal evaluation. All blood samples were sentrifuged and plasma was extracted immediately, and stored at '-20C'.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33832
0
Query!
Address
33832
0
Query!
Country
33832
0
Query!
Phone
33832
0
Query!
Fax
33832
0
Query!
Email
33832
0
Query!
Contact person for public queries
Name
17079
0
YAVUZ AYDIN
Query!
Address
17079
0
atakent mah.soyakolimpiakent sitesi.D blok No:53 Halkali/Kucukcekmece 34303 Istanbul
Query!
Country
17079
0
Turkey
Query!
Phone
17079
0
+902126954830
Query!
Fax
17079
0
Query!
Email
17079
0
[email protected]
Query!
Contact person for scientific queries
Name
8007
0
Yavuz Aydin
Query!
Address
8007
0
atakent mah.soyakolimpiakent sitesi.D blok No:53 Halkali/Kucukcekmece 34303 Istanbul
Query!
Country
8007
0
Turkey
Query!
Phone
8007
0
+902126954830
Query!
Fax
8007
0
Query!
Email
8007
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF